H. Gregory

发表

Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

W. Chung, P. Hall, V. Pankratz, 2013, PLoS genetics.

Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

Jane E. Carpenter, Jaana M. Hartikainen, W. Chung, 2019, Nature Genetics.

Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study☆

R. Eeles, D. Easton, A. Antoniou, 2020, European urology.

Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study

R. Eeles, D. Easton, A. Antoniou, 2018, Genetics in Medicine.

Prostate Cancer Risk by BRCA2 Genomic Regions

R. Eeles, D. Easton, A. Antoniou, 2020, European urology.

Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

W. Chung, P. Hall, V. Pankratz, 2013, PLoS Genetics.

Guidelines for Follow-Up of Women at High Risk for Inherited Breast Cancer: Consensus Statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer

J. Chang-Claude, K. Heimdal, P. Møller, 2002, Disease markers.

Aberdeen Genetic Clinic

N. Haites, A. Schofield, H. Gregory, 2004 .

Ascertainment of familial ovarian cancer in the Aberdeen Genetic Clinic.

N. Haites, A. Schofield, D. de Silva, 1996, Journal of medical genetics.

Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus

A. Whittemore, L. Kiemeney, S. Cross, 2016, Nature Communications.

Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2

Mads Thomassen, Stephen Fox, Dieter Niederacher, 2011, Breast Cancer Research.

Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.

Diana Eccles, Susan Peock, Rosemarie Davidson, 2013, Journal of the National Cancer Institute.

Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

Jane E. Carpenter, Jack A. Taylor, W. Chung, 2019, Nature Genetics.

University of Groningen Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk Couch,

F. Couch, B. Bonanni, O. Olopade, 2013 .

Non-uptake of predictive genetic testing for BRCA1/2 among relatives of known carriers: attributes, cancer worry, and barriers to testing in a multicenter clinical cohort.

S. Ashley, R. Eeles, D. Evans, 2004, Genetic testing.

Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores

F. Couch, O. Olopade, J. Benítez, 2021, Journal of the National Cancer Institute.

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

Jane E. Carpenter, Jack A. Taylor, W. Chung, 2021, Nature Communications.

The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant

W. Chung, F. Couch, O. Olopade, 2021, Genetics in Medicine.

Predicting breast cancer risk: implications of a “weak” family history

M. Longmuir, D. Goudie, N. Bradshaw, 2008, Familial Cancer.

Prospective surveillance of women with a family history of breast cancer: auditing the risk threshold

M. Longmuir, D. Goudie, N. Bradshaw, 2008, British Journal of Cancer.

Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers.

F. Couch, B. Karlan, J. Benítez, 2011, Journal of the National Cancer Institute.

Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status

A. Howell, P. Møller, D. Evans, 2007, International journal of cancer.

Risk reducing mastectomy: outcomes in 10 European centres

A. Howell, P. Møller, D. Eccles, 2008, Journal of Medical Genetics.

Efficacy of Early Diagnosis and Treatment in Women with a Family History of Breast Cancer

K. Heimdal, P. Møller, G. Evans, 2002, Disease Markers.

Efficacy of early diagnosis and treatment in women with a family history of breast cancer. European Familial Breast Cancer Collaborative Group.

K. Heimdal, P. Møller, G. Evans, 1999, Disease markers.

Efficacy of Early Diagnosis and Treatment in Women with a Family History of Breast Cancer

K. Heimdal, P. Møller, G. Evans, 2002, Disease Markers.

Survival in prospectively ascertained familial breast cancer: Analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy

A. Howell, K. Heimdal, P. Møller, 2002, International journal of cancer.

Male breast cancer: the importance of recognizing family history and the preliminary results of linkage analysis to BRCA1 and BRCA2

N. Haites, A. Schofield, H. Gregory, 1996 .

No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study

F. Couch, I. Ellis, T. Rebbeck, 2009, Breast Cancer Research and Treatment.

Risk estimation for familial breast cancer: improving the system of counselling

N. Haites, B. Wilson, S. Wordsworth, 2007, European Journal of Human Genetics.

Teaching undergraduates about familial breast cancer: comparison of a computer assisted learning (CAL) package with a traditional tutorial approach

Z. Miedzybrodzka, N. Haites, J. Mollison, 2001, European Journal of Human Genetics.

A Genome-Wide Association Study of Type 2 Diabetes in Finns Detects Multiple Susceptibility Variants

N. Rahman, M. Thomas, R. Houlston, 2010 .

Cancer Genetics Services in Europe

J. Chang-Claude, P. Møller, D. Eccles, 2002, Disease markers.

Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

Jane E. Carpenter, Jack A. Taylor, W. Chung, 2019, Nature Communications.

Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.

R. Eeles, D. Easton, A. Antoniou, 2013, Journal of the National Cancer Institute.

Peer Reviewed Title

B. Bonanni, O. Olopade, B. Karlan, 2012 .